Biarylcarboxamide inhibitors of phosphodiesterase IV and tumor necrosis factor-α
Tumor necrosis factor (TNF-α) has been implicated as a key mediator in the progression of rheumatoid arthritis. Inhibitors of phosphodiesterase IV (PDE IV) have been shown to inhibit the production of TNF-α by elevating intracellular levels of cyclic adenosine monophosphate (cAMP). Our efforts in a series of biarylcarboxamides have lead to the identification of 8j (CP-353,164) as a potent inhibitor of PDE IV and TNF-α.
References (14)
- et al.
Lancet
(1994) - et al.
Int. J. Immunopharmac.
(1994) Tetrahedron
(1992)- et al.
Clin. Exp. Immunol.
(1995) - et al.
Am. J. Resp. Crit. Care Med.
(1994) Drugs of the Future
(1995)- et al.
J. Org. Chem.
(1993)
There are more references available in the full text version of this article.
Cited by (15)
Design, synthesis, and evaluation of 2-aryl-7-(3′,4′-dialkoxyphenyl)-pyrazolo[1,5-a]pyrimidines as novel PDE-4 inhibitors
2010, Bioorganic and Medicinal Chemistry LettersSynthesis and biological evaluation of novel phthalazinone derivatives as topically active phosphodiesterase 4 inhibitors
2009, Bioorganic and Medicinal ChemistrySynthesis and evaluation of a novel series of phosphodiesterase IV inhibitors. A potential treatment for asthma
1998, Bioorganic and Medicinal Chemistry LettersChapter 10. Phosphodiesterases 4 Inhibitors
1998, Annual Reports in Medicinal ChemistrySAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3- α]pyridines as potent inhibitors of human eosinophil phosphodiesterase
2007, Journal of Medicinal Chemistry
Copyright © 1997 Published by Elsevier Ltd.